Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study

Table 1 The characteristics of the patients

	BuCy	BuFlu	P value
No. of patients	54	54
Sex male/female	27/27	25/29	0.700
Median age in years (range)	30.5(12 ~ 52)	30.5(14 ~ 54)	0.518
Genetic subgroups favorable/intermediate/poor risk/unknown	2/24/16/12	9/25/14/6	0.085
Induction chemotherapy cycles (range)	1 (1–3)	1 (1–3)	0.056
Consolidation chemotherapy cycles (range)	2.5 (1–4)	2 (1–4)	0.222
Source of donors related/unrelated	47/7	45/9	0.588
HLA typing matched/mismached	48/6	46/8	0.567
Source of stem cells PB /BM + PB	48/6	50/4	0.507
Cell yield (median) MNC(10⁸/Kg)	7.87	7.22	0.510
CD34 + (10⁶/Kg)	7.30	5.92	0.112

Abbreviations: BuCy, busulfan-cyclophosphamide; BuFlu, busulfan-fludarabine;
BM, bone marrow; PB, peripheral blood; MNC, mononucleated cell.

ISSN: 1756-8722